Success Stories: NIW Petition Approved for Hematology and Medical Oncology Fellow in Nebraska in the Field of Clinical and Translational Medicine
Client’s Testimonial:
Thank you so much! … I have already been referring my friends to you… I will also tell others about your excellent work.
Position at the Time of Case Filing: Hematology and Medical Oncology Fellow
Country of Origin: India
Service Center: Nebraska Service Center (NSC)
State of Residence at the Time of Filing: Nebraska
Approval Notice Date: July 8th, 2014
Processing Time: 3 months, 18 days
The client that North America Immigration Law Group – WeGreened.com had the opportunity to work in this case was a Hematology and Medical Oncology Fellow from India. His work had focused specifically on clinical and translational research within the fields of hematology and medical oncology. As a clinical physician and research scientist, he has centered his research and clinical work on diagnostics and treatment modalities for blood disorders and various cancers, such as non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, lung cancer, colorectal cancer, breast cancer and prostate cancer. We successfully demonstrated that his continued employment in the field would benefit those in his field, as well as the citizens of the United States at large. In order for our client’s case to be successful, we submitted extensive documentation proving his highly significant contributions to his field, including 11 peer-reviewed journal articles, 1 book chapter, and 17 abstract papers. His publications had been cited at least 50 times at the time we filed the case; nearly all of the citations were by independent researchers around the world, demonstrating that these publications are widely recognized and relied upon in the field. The inherit merit of his work was confirmed in the following quote from an independent recommender, “[Client] showed that the progression free and overall survival rates in patients with grades I and II follicular lymphoma when Rituximab was or was not used and when it was used later in a diagnosis. His results revealed the overall survival rates for patients with low grade follicular lymphoma are greatly improved when rituximab is used upfront. Studies like this are critical from both a research and a clinical perspective.” Through extensive documentation, we were able to successfully argue that our client would serve the national interest to a significantly greater degree than others with similar education and experience. His NIW petition was approved in 3 months and 18 days.